Acetate reduces PGE2 release and modulates phospholipase and cyclooxygenase levels in neuroglia stimulated with lipopolysaccharide

Lipids

Volumn 48, Issue 7, 2013, Pages 651-662

  Soliman, Mahmoud L ^a   Ohm, Joyce E ^a   Rosenberger, Thad A ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Acetate; Cyclooxygenase; Eicosanoid; Histone acetylation; Phospholipase

Indexed keywords

ACETIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HISTONE H3; INTERLEUKIN 1BETA; INTERLEUKIN 4; PHOSPHOLIPASE A2; PHOSPHOLIPASE C BETA1; PROSTAGLANDIN E2; SECRETORY PHOSPHOLIPASE A2; TRANSCRIPTION FACTOR RELA; HISTONE; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; PHOSPHOLIPASE C BETA; PTGS1 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; ASTROCYTE; BINDING AFFINITY; CELL LEVEL; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HISTONE ACETYLATION; INTRACELLULAR SIGNALING; MICROGLIA; MOUSE; NONHUMAN; PROSTAGLANDIN RELEASE; ACETYLATION; ANIMAL; BRAIN; C57BL MOUSE; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROMOTER REGION; SECRETION (PROCESS); SIGNAL TRANSDUCTION; DRUG EFFECT;

RATTUS;

ACETIC ACID; ACETYLATION; ANIMALS; ASTROCYTES; BRAIN; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION; HISTONES; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICROGLIA; PHOSPHOLIPASE C BETA; PHOSPHOLIPASES A2; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84879687458     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-013-3799-x     Document Type: Article

References (59)

1. Arun P, Madhavarao CN, Moffett JR, Hamilton K, Grunberg NE, Ariyannur PS, Gahl WA, Anikster Y, Mog S, Hallows WC, Denu JM, Namboodiri AM (2010) Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. J Inherit Metab Dis 33:195-210
2. Arun P, Ariyannur PS, Moffett JR, Xing G, Hamilton K, Grunberg NE, Ives JA, Namboodiri AM (2010) Metabolic acetate therapy for the treatment of traumatic brain injury. J Neurotrauma 27:293-298
3. Reisenauer CJ, Bhatt DP, Mitteness DJ, Slanczka ER, Gienger HM, Watt JA, Rosenberger TA (2011) Acetate supplementation attenuates lipopolysaccharide- induced neuroinflammation. J Neurochem 117:264-274
4. Brissette CA, Houdek HM, Floden AM, Rosenberger TA (2012) Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis. J Neuroinflammation 9:249
5. Bhatt DP, Houdek HM, Watt JA, Rosenberger TA (2013) Acetate supplementation increases brain phosphocreatine and reduces AMP levels with no effect on mitochondrial biogenesis. Neurochem Int 62:296-305
6. Soliman ML, Rosenberger TA (2011) Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression. Mol Cell Biochem 352:173-180
7. Soliman ML, Smith MD, Houdek HM, Rosenberger TA (2012) Acetate supplementation modulates brain histone acetylation and decreases interleukin-1beta expression in a rat model of neuroinflammation. J Neuroinflammation 9:51
8. Soliman ML, Puig KL, Combs CK, Rosenberger TA (2012) Acetate reduces microglia inflammatory signaling in vitro. J Neurochem 123:555-567
9. Soliman ML, Combs CK, Rosenberger TA (2013) Modulation of inflammatory cytokines and mitogen-activated protein kinases by acetate in primary astrocytes. J Neuroimmune Pharmacol 8:287-300
10. Lima IV, Bastos LF, Limborco-Filho M, Fiebich BL, de Oliveira AC (2012) Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm 2012:946813
11. Phillis JW, O'Regan MH (2004) A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Brain Res Rev 44:13-47
12. 2 and its role in brain tissue. J Neurochem 69:889-901
13. 2. J Biol Chem 269:13057-13060
14. Balboa MA, Varela-Nieto I, Killermann Lucas K, Dennis EA (2002) Expression and function of phospholipase A2 in brain. FEBS Lett 531:12-17
15. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182
16. Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med 12:133-148
17. Fujimori Y, Murakami M, Kim DK, Hara S, Takayama K, Kudo I, Inoue K (1992) Immunochemical detection of arachidonoyl-preferential phospholipase A2. J Biochem 111:54-60
18. Lauritzen I, Heurteaux C, Lazdunski M (1994) Expression of group II phospholipase A2 in rat brain after severe forebrain ischemia and in endotoxic shock. Brain Res 651:353-356
19. Farooqui AA, Horrocks LA (2005) Signaling and interplay mediated by phospholipases A2, C, and D in LA-N-1 cell nuclei. Reprod Nutr Dev 45:613-631
20. Grinberg S, Hasko G, Wu D, Leibovich SJ (2009) Suppression of PLCbeta2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am J Pathol 175:2439-2453
21. Adibhatla RM, Hatcher JF (2007) Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain Res 1134:199-205
22. Hiller G, Sundler R (1999) Activation of arachidonate release and cytosolic phospholipase A2 via extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in macrophages stimulated by bacteria or zymosan. Cell Signal 11:863-869
23. Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ, Jakubowski JA (1996) p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271:27723-27729
24. Gorisch SM, Wachsmuth M, Toth KF, Lichter P, Rippe K (2005) Histone acetylation increases chromatin accessibility. J Cell Sci 118:5825-5834
25. Anderson JD, Lowary PT, Widom J (2001) Effects of histone acetylation on the equilibrium accessibility of nucleosomal DNA target sites. J Mol Biol 307:977-985
26. Polach KJ, Lowary PT, Widom J (2000) Effects of core histone tail domains on the equilibrium constants for dynamic DNA site accessibility in nucleosomes. J Mol Biol 298:211-223
27. Krajewski WA, Becker PB (1998) Reconstitution of hyperacetylated, DNase I-sensitive chromatin characterized by high conformational flexibility of nucleosomal DNA. Proc Natl Acad Sci U S A 95:1540-1545
28. Mu C, Liu H, Zheng GC (2007) The modification and variants of histone. Mol Biol (Mosk) 41:395-407
29. Eberharter A, Becker PB (2002) Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 3:224-229
30. Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23
31. Polevoda B, Sherman F (2002) The diversity of acetylated proteins. Genome Biol 3:6.1-6.6
32. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321:892-901
33. Rouaux C, Panteleeva I, Rene F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L, Menger Y, Boutillier AL, Loeffler JP (2007) Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 27:5535-5545
34. Zhang B, West EJ, Van KC, Gurkoff GG, Zhou J, Zhang XM, Kozikowski AP, Lyeth BG (2008) HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 1226:181-191
35. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A 100:4281-4286
36. McCampbell A, Taye AA, Whitty L, Penney E, Steffan JS, Fischbeck KH (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci U S A 98:15179-15184
37. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu YZ, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743
38. Langley B, Gensert JM, Beal MF, Ratan RR (2005) Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 4:41-50
39. Blanchard F, Chipoy C (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10:197-204
40. Adcock IM (2007) HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 150:829-831
41. Dhawan G, Floden AM, Combs CK (2012) Amyloid-beta oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging 33:2247-2261
42. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41-45
43. Rice JC, Allis CD (2001) Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 13:263-273
44. Hein AM, Stutzman DL, Bland ST, Barrientos RM, Watkins LR, Rudy JW, Maier SF (2007) Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1bata injections into the dorsal hippocampus. Neuroscience 150:754-763
45. Sun GY, Xu J, Jensen MD, Yu S, Wood WG, Gonzalez FA, Simonyi A, Sun AY, Weisman GA (2005) Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol Neurobiol 31:27-41
46. Quan N, Whiteside M, Herkenham M (1998) Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. Brain Res 802:189-197
47. Yermakova A, O'Banion MK (2000) Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6:1755-1776
48. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A 100:5473-5478
49. Hein AM, O'Banion MK (2009) Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol 40:15-32
50. Casolini P, Catalani A, Zuena AR, Angelucci L (2002) Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 68:337-343
51. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131:651-664
52. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S, Panikashvili D, Shohami E, Jansen SA, Narayan RK, Strauss KI (2005) Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 56:590-604
53. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 98:1294-1299
54. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88:576-582
55. Silva PF, Garcia VA, Dornelles Ada S, Silva VK, Maurmann N, Portal BC, Ferreira RD, Piazza FC, Roesler R, Schroder N (2012) Memory impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and ameliorated by sodium butyrate. Neuroscience 200:42-49
56. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A (2011) Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 26:187-197
57. Anthonsen MW, Solhaug A, Johansen B (2001) Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha- and interleukin-1beta-induced NF-kappa B activation. J Biol Chem 276:30527-30536
58. Jupp OJ, Vandenabeele P, MacEwan DJ (2003) Distinct regulation of cytosolic phospholipase A2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes. Biochem J 374:453-461
59. Deng WG, Zhu Y, Wu KK (2003) Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem 278:4770-4777